# A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

> **NCT02925117** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 167 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02925117
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-25
- **Primary completion:** 2017-08-10
- **Final completion:** 2019-01-31
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02925117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02925117, "A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02925117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*